# ROR1

Source: https://onco.cc/targets/ror1/  
OnCo record `ror1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ROR1 is a fetal pseudo-kinase receptor re-expressed on over 90% of chronic lymphocytic leukaemias, 30 to 50% of diffuse large B-cell lymphomas and 40 to 60% of triple-negative breast cancers, and largely absent from healthy adult tissue. Zilovertamab vedotin uses it as an ADC address, in phase 3 in large B-cell lymphoma; whether expression level predicts benefit is unproven.

## Summary

ROR1 is an oncofetal receptor tyrosine kinase-like protein, a Wnt5a pseudo-kinase receptor that drives survival signalling in CLL and mantle cell lymphoma and is largely absent from normal adult tissue. Surface expression is seen in over 90% of CLL, 30-50% of DLBCL, and 40-60% of TNBC by IHC, with NSCLC expression also reported. Zilovertamab vedotin (MK-2140), an ADC, is in phase 3 in DLBCL, and the TNBC and NSCLC expression supports solid-tumour programmes. Because the receptor is a pseudo-kinase, it is used as a delivery address rather than a signalling target, and whether expression level predicts ADC benefit remains to be shown. The simple version is an embryonic receptor that many cancers re-express, giving ADCs a target largely missing from healthy cells.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: adc-target
- Symbol: ROR1
- Class: surface-antigen
- Biology: Wnt5a pseudo-kinase receptor; drives survival signalling in CLL and MCL.
- Where found: CLL; Mantle cell lymphoma; DLBCL; TNBC; NSCLC

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/ROR1
- Wikipedia: https://en.wikipedia.org/wiki/ROR1

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Zilovertamab vedotin](https://onco.cc/drugs/zilovertamab-vedotin/)
- trials: [Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC](https://onco.cc/trials/nct07510802/), [waveLINE-003](https://onco.cc/trials/waveline-003/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- people: [Stanley R. Riddell](https://onco.cc/people/stanley-riddell/)
- institutions: [UC San Diego Moores Cancer Center](https://onco.cc/institutions/ucsd-moores/)

---
JSON: https://onco.cc/api/v1/entities/ror1.json